Yan Rong1, Fei Wang2, Xiaoli Li1, Xinhua Liang3, Yang Zhou1, Dandan Zhang1, Jing Liu4, Huadong Zeng1, Jing Wang5, Yi Shi6. 1. Department of Respiratory and Critical Care Medicine, Shenzhen Hospital, Southern Medical University Shenzhen 518100, China. 2. Department of Orthopaedics, The University of Hong Kong - Shenzhen Hospital Shenzhen 518053, China. 3. Department of Nephrology, Shenzhen Hospital, Southern Medical University Shenzhen 518100, China. 4. Department of Health Management Center, Shenzhen Hospital, Southern Medical University Shenzhen 518100, China. 5. Department of Radiology, Shenzhen Hospital, Southern Medical University Shenzhen 518100, China. 6. Department of Respiratory and Critical Care Medicine, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University Nanjing 210002, China.
Abstract
BACKGROUND: Correlation of SARS-CoV-2 serum antibodies with COVID-19 development and outcome has not been fully studied. Due to the time dynamic of antibodies, the antibody concentration of the same patient varies greatly at different times during the course of the disease. Therefore, our study used IgM/T or IgG/T (the ratio of serum antibody concentration to days after symptom onset) to reflect the patient's humoral immune status, and analyzed their correlation with COVID-19 development and outcome. METHODS: Clinical data of 50 non-critical COVID-19 patients were retrospectively analyzed. Time-resolved fluorescence immunochromatography was used to quantitatively detect SARS-CoV-2 IgM and IgG. Correlation analysis was performed. RESULTS: IgM antibody was positive on day 5 of symptom onset, increased within 2 weeks, and then gradually decreased. However, IgG antibody was positive on week 2 of symptom onset and continued to increase since. Additionally, IgM/T, but not IgG/T of recovery period (Spearman ρ=0.17; P=0.283), was negatively correlated with disease course in 2 weeks of symptom onset (Spearman ρ=-0.860; P=0.000). IgG/T of recovery period was positively correlated with clinical classification (Spearman ρ=0.432; P=0.004), number of involved lung lobes (Spearman ρ=0.343; P=0.026), and lung lesions (Spearman ρ=0.472; P=0.002). CONCLUSIONS: Within 2 weeks of symptom onset, higher IgM/T indicates faster recovery and shorter disease course. In recovery period, higher IgG/T suggests more serious disease. IgM/T or IgG/T may predict disease severity and outcome in non-critical COVID-19 patients. AJTR
BACKGROUND: Correlation of SARS-CoV-2 serum antibodies with COVID-19 development and outcome has not been fully studied. Due to the time dynamic of antibodies, the antibody concentration of the same patient varies greatly at different times during the course of the disease. Therefore, our study used IgM/T or IgG/T (the ratio of serum antibody concentration to days after symptom onset) to reflect the patient's humoral immune status, and analyzed their correlation with COVID-19 development and outcome. METHODS: Clinical data of 50 non-critical COVID-19patients were retrospectively analyzed. Time-resolved fluorescence immunochromatography was used to quantitatively detect SARS-CoV-2 IgM and IgG. Correlation analysis was performed. RESULTS: IgM antibody was positive on day 5 of symptom onset, increased within 2 weeks, and then gradually decreased. However, IgG antibody was positive on week 2 of symptom onset and continued to increase since. Additionally, IgM/T, but not IgG/T of recovery period (Spearman ρ=0.17; P=0.283), was negatively correlated with disease course in 2 weeks of symptom onset (Spearman ρ=-0.860; P=0.000). IgG/T of recovery period was positively correlated with clinical classification (Spearman ρ=0.432; P=0.004), number of involved lung lobes (Spearman ρ=0.343; P=0.026), and lung lesions (Spearman ρ=0.472; P=0.002). CONCLUSIONS: Within 2 weeks of symptom onset, higher IgM/T indicates faster recovery and shorter disease course. In recovery period, higher IgG/T suggests more serious disease. IgM/T or IgG/T may predict disease severity and outcome in non-critical COVID-19patients. AJTR
Authors: Patrick C Y Woo; Susanna K P Lau; Beatrice H L Wong; Kwok-hung Chan; Chung-ming Chu; Hoi-wah Tsoi; Yi Huang; J S Malik Peiris; Kwok-yung Yuen Journal: Clin Diagn Lab Immunol Date: 2004-07
Authors: Jenni Virtanen; Ruut Uusitalo; Essi M Korhonen; Kirsi Aaltonen; Teemu Smura; Suvi Kuivanen; Sari H Pakkanen; Sointu Mero; Anu Patjas; Marianna Riekkinen; Anu Kantele; Visa Nurmi; Klaus Hedman; Jussi Hepojoki; Tarja Sironen; Eili Huhtamo; Olli Vapalahti Journal: Viruses Date: 2021-05-26 Impact factor: 5.048